Full-Time

Associate Manager Managed Access Program

Posted on 9/10/2026

Deadline 11/15/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's

Category
Project & Program Management (1)
Required Skills
Power BI
SharePoint
Microsoft Office
ServiceNow

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • At least 7 years of experience in the pharmaceutical industry, including access management or clinical study management, project management, and medical operations activities.
  • Strong written and verbal communication skills.
  • Strong administrative and organizational skills.
  • Proficiency in Microsoft Office.
  • Excellent spoken and written English.
  • A bachelor's degree or higher in science.
Responsibilities
  • Identify Managed Access requests belonging to Sanofi or an affiliate from the Sanofi or affiliate portal and track them through review until the decision is communicated to the requesting physician.
  • Own the case submission process, including verifying documentation completeness, communicating with Global Medical, recording decisions, and conducting country follow-up in compliance with the Managed Access Program standard operating procedure.
  • Process all received Managed Access Program requests within agreed turnaround times and quality standards.
  • Store and manage documentation for all processed requests.
  • Support internal audits for the Managed Access Program process and documentation.
  • Support queries from healthcare professionals and local medical teams regarding Managed Access requests.
  • Support the Global Managed Access Program team in executing projects.
  • Comply with quality practices and notify stakeholders of deviations.
  • Support Managed Access requests through MRPTC processes where applicable.
  • Upload and organize relevant documentation within the SharePoint site and maintain an audit-ready environment.
  • Process Pre-Registration Import Licenses and Restricted Import Licenses.
  • Support the establishment of new processes or systems by working with the Governance and Operations Leads.
  • Support affiliates during Managed Access request-management process transitions and requests by collaborating with the Operations Lead and affiliate stakeholders.
  • Serve as the primary point of contact for local medical teams globally regarding Managed Access questions, case submissions, and process inquiries.
  • Respond to internal and external inquiries regarding Sanofi or affiliate Managed Access Programs.
  • Liaise and coordinate with Global and Local Medical, Project Management, and Quality colleagues.
  • Provide reports and Managed Access Program updates to global medical teams as needed.
  • Maintain global contact lists for Managed Access communications.
  • Ensure deliverables meet required timelines and quality targets and comply with requirements.
  • Manage timely storage and retrieval of documents related to Managed Access requests.
  • Escalate Managed Access requests to the MRPTC process and manage the related documentation.
  • Share MRPTC meeting notes with relevant stakeholders and communicate appropriate actions.
  • Adhere to affiliate processes when processing affiliate requests.
  • Receive and track all Managed Access requests for the assigned portfolio, ensuring evaluation and response to the requesting physician are completed promptly.
  • Identify best practices and operational efficiencies within the assigned Managed Access portfolio.
  • Participate in cross-functional Global Managed Access meetings to understand and anticipate pipeline products eligible for Managed Access.
  • Assist medical teams in liaising with the Global team or MRPTC secretary for requests requiring escalation.
  • Own Managed Access documentation, including criteria, application forms, decision letters, and training manuals.
  • Partner with Medical, Legal, and Compliance teams to ensure documentation meets patient privacy requirements and disease-specific guidelines.
  • Prepare and provide documentation for audit-related activities to ensure compliance with Sanofi policies and procedures at local, regional, and global levels.
Desired Qualifications
  • ServiceNow experience.
  • Power BI experience.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.